- You can view the full Regeneron Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
The $639 million deal marks the the third purchase for Brent Saunders since early August.
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said today that trials of their cholesterol drug Praulent met targets.
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.